Jump to content

Dario Altieri

From Wikipedia, the free encyclopedia
Dario Carlo Altieri
Occupation(s)President and CEO

Dario Carlo Altieri, an Italian-born physician-scientist, is the president and CEO of The Wistar Institute[1] in Philadelphia.[2] He is also the holder of the Robert and Penny Fox Distinguished Professor and the director of the National Cancer Institute-designated Ellen and Ronald Caplan Cancer Center at The Wistar Institute.

Biography

[edit]

Altieri was born in Milan, Italy, where he attended the University of Milan Medical School. He trained in internal medicine with a postgraduate specialty degree in clinical and experimental hematology. In 1987, he joined the Scripps Clinic and Research Foundation in La Jolla, California, as a research fellow before becoming a faculty member.[3] In 1994, Altieri became an associate professor in the Department of Pathology, Boyer Center for Molecular Medicine at Yale University School of Medicine, and was promoted to full professor in 1999.[3] In 2002, he became the founding Chair of the Department of Cancer Biology at the University of Massachusetts Medical School.[1][4]

Research

[edit]

His research has focused on Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells. His work has identified survivin, one of these IAP genes, is over-produced in almost every human cancer, and his team is currently studying the biology of survivin and how it could be used to develop treatments for cancer.[5][6][7]

Altieri has also been involved in the development of gamitrinib, a Hsp90 inhibitor that was shown to disable the activity of mitochondria in cancerous cells.

In 2013, Altieri and his team received a $1.5 million grant from the United States Department of Defense to prepare the drug for human trials.[8][9] He also co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.[10]

Further reading

[edit]
  • "Dario C. Altieri Inventions, Patents and Patent Applications". Justia Patents Search. 2021-12-23. Retrieved 2023-03-15.<
  • "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer - Full Text View". ClinicalTrials.gov. 2021-04-01. Retrieved 2023-03-15.

References

[edit]
[edit]